BHVN Biohaven Ltd.

NYSE
$13.24

Biohaven Ltd. (BHVN) is expected to report earnings on January 28, 2027, after the market close. The consensus earnings estimate is a loss of $0.35 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.4% since its last earnings release on October 29, 2026.

Biohaven Missed Consensus Estimates
Thursday, October 29, 2026 · 4:02 PM ET
Earnings Date
4th Quarter, Dec 2026
Jan 28
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.35)
Rev est $255M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $14.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Biohaven Ltd.

Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.